Strategic Partnership APS recently became part of NAMSA, signaling broader capabilities, extended reach, and potential for integrated preclinical services across a larger CRO network to offer comprehensive packages to medical device and pharmaceutical clients.

RegulatoryAdherence With AAALAC, ISO17025, USDA registration, and GLP compliance, APS presents a highly credible option for clients seeking rigorous, compliant preclinical testing to de-risk regulatory submissions.

SpecializedCapabilities Expertise spans ISO10993 biocompatibility, USP testing, interventional and surgical studies, toxicology and pharmacology, plus animal model development and pathology—meeting diverse testing needs under one roof.

BiotechEngagement Recent collaboration with Recombinetics for glioblastoma research highlights APS’s appeal to gene editing and advanced biotech clients seeking preclinical support for innovative therapies.

ScaleOpportunity Mid-size CRO with 51-200 employees and $25M–$50M revenue sits between boutique and large CROs, offering nimble project management combined with robust capabilities to win mid- to late-stage preclinical programs and ongoing GLP studies.